Gene therapy is at the forefront of medicine that utilizes genetic materials to treat or prevent diseases, including neurodegenerative diseases such as Huntington’s disease (HD). While dysregulation of dopamine transmission plays a key role in HD, little is known about the relationship between dopamine and the principal cause of HD, the production of mutant huntingtin protein due to the limitation on visualization of dopamine dynamics at the spatiotemporal resolution of both neuromodulator release (milliseconds) and boutons (microns). Creative Biolabs has invited Dr. Markita Landry to walk us through how her team developed a near Infrared Catecholamine nanosensor (nIRCat) and used real-time imaging to find out what drives late-disease decreases in evoked dopamine release, and how to use these findings as optimal therapeutic intervention timepoints for siRNA-based HD therapies. More can be found at https://www.creative-biolabs.com/gene-therapy/webinar-towards-optimal-therapeutic-intervention-timepoints-for-gene-therapy.htm.

Bispecific antibodies (bsAbs) can simultaneously bind to two separate and unique epitopes on the same or different antigens, sparking intense interest among the scientific community in recent years. Their dual specificity for soluble antigens has been explored extensively for various therapeutic applications, including cancer therapies and virus neutralization. Creative Biolabs has invited Dr. Archana Thakur and Dr. Luca Varani to walk us through how they utilize the power of bsAbs to 1) arm "headless CAR T cells" and serially kill tumor targets and 2) neutralize wild-type SARS-CoV-2 and its variants and suppress viral escape. New insights you will learn through the following two key topics we will discuss in this webinar: 1. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells The design of bsAb armed metabolically enhanced headless CAR T cells (hCART) The generation of bsAb armed metabolically enhanced hCART The efficacy of bsAb armed metabolically enhanced hCART in preclinical studies 2. Bispecific Antibody Protects from SARS-CoV-2 Variants of Concern and Prevents Viral Escape in Mice The development of the bispecific IgG1-like molecule (CoV-X2) CoV-X2 neutralizes wild-type SARS-CoV-2 and its variants in preclinical studies CoV-X2 protects mice from infection and suppresses viral escape For more information, please visit at: https://www.creative-biolabs.com/bsab/Webinar-Harnessing-the-Power-of-Bispecific-Antibodies.htm.